European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer
Retrieved on:
Friday, August 19, 2022 - 3:47am
Oncology, Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, FDA, III, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Recurrence, Endothelium, Safety, Association, American Association, Genentech, Senior, European Directive on Traditional Herbal Medicinal Products, Committee, Cervical cancer, European Medicines Agency, EC, Cancer, CGMP, KDR, Efficacy, NSCLC, Marketing, Patient, Biosimilar, Large-cell lung carcinoma, Metastasis, American Association for Cancer Research, Celltrion, CHMP, AACR, Medication package insert, VEGF, Colon, Committee for Medicinal Products for Human Use, Neoplasm, State, US, MedImmune, Inc. v. Genentech, Inc., Royal commission, Ovarian cancer, Bevacizumab, European Commission, Food, Product, EMA, Rectum, Health care, Medical imaging, Pharmaceutical industry, European, EU
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
Key Points:
- Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer.
- The European Commissions approval of Vegzelma will increase access to treatment for patients living with certain types of cancer at an affordable price, said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare.
- The EC approval of Vegzelma follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2022.
- Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.